Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
73 hedge funds and large institutions have $226M invested in Kindred Biosciences, Inc. in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 18
48% more capital invested
Capital invested by funds: $153M → $226M (+$73.6M)
16% more funds holding
Funds holding: 63 → 73 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $352K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.51M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$8.24M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$4.45M |
| 4 |
Renaissance Technologies
New York
|
+$2.47M |
| 5 |
BlackRock
New York
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.15M |
| 2 |
RA
Royce & Associates
New York
|
-$1.09M |
| 3 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$1.07M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$370K |
| 5 |
Citigroup
New York
|
-$297K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RA
76
Royce & Associates
New York
| – | -$1.09M | -126,000 | Closed |
|
77
D.E. Shaw & Co
New York
| – | -$114K | -13,163 | Closed |
|
|
WS
78
Wedbush Securities
Los Angeles,
California
| – | -$87K | -10,000 | Closed |
|
|
CMBA
79
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$79K | -9,145 | Closed |
|
|
PA
80
Parallel Advisors
San Francisco,
California
| – | -$10.5K | -1,075 | Closed |
|
KIN Hedge Fund Activity: Q2 2018 in Review
73 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2018, worth a combined $226M — up 48% from $153M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KIN positions and 6 closed out — a net gain of 10 holders — while 30 added to existing stakes and 18 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $9.51M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.15M sold.
- 73 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2018, up from 63 in Q1 2018.
- Funds reported $226M of Kindred Biosciences, Inc. stock for Q2 2018, up 48% quarter-over-quarter.
- 16 funds opened new Kindred Biosciences, Inc. positions in Q2 2018 and 6 closed out, a net change of +10 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2018 was Adage Capital Partners, an estimated $9.51M added.
- The largest Kindred Biosciences, Inc. seller in Q2 2018 was EcoR1 Capital, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2018.